In exploratory biomarker analyses from IMmotion150 (phase II trial comparing first-line treatment in RCC with the combination of Atezolizumab with or without Bevacizumab versus standard therapy with Sunitinib), the high expression of the T-effector gene signatures was associated with the high expression of PD-L1 and CD8+ TILs and improved PFS with Atezolizumab/Bevacizumab versus Sunitinib, while no differences in comparison to Atezolizumab monotherapy were found [29]. This evidence concerns the gene CD8A and renal cell carcinoma.